Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director - Srdan Verstovsek, MD,PhD
M.D. Anderson Cancer Center
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
102 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Brisbane, Australia
- Facility name not stated
Parkville, Australia
- Facility name not stated
Tweed Heads, Australia
- Facility name not stated
Antwerp, Belgium
- Facility name not stated
Bruges, Belgium
- Facility name not stated
Brussels, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
Hamilton, Canada
- Facility name not stated
Montreal, Canada
- Facility name not stated
Toronto, Canada
- Facility name not stated
Beijing, China
- Facility name not stated
Hangzhou, China
- Facility name not stated
Avignon, France
- Facility name not stated
Bayonne, France
- Facility name not stated
Brest, France
- Facility name not stated
Lille, France
- Facility name not stated
Nantes, France
- Facility name not stated
Paris, France
- Facility name not stated
Vandœuvre-lès-Nancy, France
- Facility name not stated
Aachen, Germany
- Facility name not stated
Berlin, Germany
- Facility name not stated
Bonn, Germany
- Facility name not stated
Freiburg im Breisgau, Germany
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Jena, Germany
- Facility name not stated
Magdeburg, Germany
- Facility name not stated
Mannheim, Germany
- Facility name not stated
Minden, Germany
- Facility name not stated
München, Germany
- Facility name not stated
Ulm, Germany
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Kecskemét, Hungary
- Facility name not stated
Szeged, Hungary
- Facility name not stated
Szombathely, Hungary
- Facility name not stated
Bari, Italy
- Facility name not stated
Bergamo, Italy
- Facility name not stated
Bologna, Italy
- Facility name not stated
Florence, Italy
- Facility name not stated
Milan, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Oct 2010
- Primary completion
- 15 Jan 2014
- Completion
- 9 Feb 2018
- Last update posted
- 6 Mar 2019
- Registered enrollment
- 222
- Registry id
- NCT01243944
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.